2008
Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population
Bae SJ, Paltiel AD, Fuhlbrigge AL, Weiss ST, Kuntz KM. Modeling the Potential Impact of a Prescription Drug Copayment Increase on the Adult Asthmatic Medicaid Population. Value In Health 2008, 11: 110-118. PMID: 18237365, PMCID: PMC3476042, DOI: 10.1111/j.1524-4733.2007.00219.x.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAge FactorsAnti-Asthmatic AgentsAsthmaCost SharingDrug PrescriptionsHealth Services AccessibilityHumansInsurance, Pharmaceutical ServicesMassachusettsMedicaidModels, EconometricNebulizers and VaporizersOutcome Assessment, Health CareState Health PlansTreatment RefusalUnited StatesConceptsFrequent acute exacerbationsAcute exacerbationCopayment increaseHealth outcomesPrescription drug copaymentsLikely health outcomesDrug nonadherenceCorticosteroid useAdult asthmaticsAcute eventDrug utilizationMedicaid populationDrug copaymentsMedicaid beneficiariesPrescription drugsCopaymentsReimbursement ratesFinancial burdenExacerbationTarget populationFirst yearNet savingsOutcomesPharmacyCommonwealth of Massachusetts
2002
AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States
Walensky RP, Paltiel AD, Freedberg KA. AIDS Drug Assistance Programs: Highlighting Inequities in Human Immunodeficiency Virus–Infection Health Care in the United States. Clinical Infectious Diseases 2002, 35: 606-610. PMID: 12173137, DOI: 10.1086/341903.Peer-Reviewed Original ResearchConceptsEffective antiretroviral therapyHuman immunodeficiency virusDrug Assistance ProgramsCost-effectiveness analysisAntiretroviral therapyHIV careMedication costsImmunodeficiency virusOutpatient arenaDisease outcomePatient's placePrivate health insuranceHealth careHealth insurancePatientsAIDSCareUnited StatesMedicationsHIVInpatientsTherapyMedicaidState AIDS Drug Assistance Programs
Johri M, Paltiel A, Goldie S, Freedberg K. State AIDS Drug Assistance Programs. Medical Care 2002, 40: 429-441. PMID: 11961477, DOI: 10.1097/00005650-200205000-00008.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsCD4 Lymphocyte CountCost of IllnessCost-Benefit AnalysisDirect Service CostsDisease ProgressionEfficiency, OrganizationalEligibility DeterminationHealth Services AccessibilityHumansInsurance CoverageInsurance, Pharmaceutical ServicesLife ExpectancyMedical AssistanceModels, EconometricOrganizational InnovationQuality-Adjusted Life YearsState Health PlansUnited StatesConceptsQuality-adjusted life yearsLifetime direct medical costsLife yearsDirect medical costsDrug Assistance ProgramsAssistance programsState-transition simulation modelQuality-adjusted life expectancyADAP programEconomic performanceLife expectancyMedical costsCost-effective useLifetime costsCost dataServices Utilization SurveyState policyAIDS CostState AIDSCoverage variesComprehensive policyUtilization SurveyPolicyCare resourcesPessimistic assumptions